CD8A and myeloid sarcoma: In the study on ocrelizumab, it has been shown that CD4+ and CD8+ T-cell responses were higher in MS patients vaccinated at early time points, i.e., one to three months after the last ocrelizumab application compared with MS patients not receiving DMTs [18].